WALTHAM, Mass.–(BUSINESS WIRE)–Palleon Pharmaceuticals, a clinical-stage company pioneering glyco-immunology drug development to treat cancer and inflammatory diseases, today announced that it will present on GLIMMER-01, the ongoing Phase 1/2 Trial of its lead program E-602 Bi-Sialidase at the Society for Immunotherapy of Cancer’s 37th Annual Meeting taking place in Boston from November 8-12, 2022. E-602 Bi-Sialidase is a first-in-class, glyco-immune checkpoint inhibitor which restores anti-tumor immunity by enzymatically degrading immunosuppressive sialoglycans in hypersialylated tumors and immune cells.
The Trials-in-Progress poster will include the specifics of the GLIMMER-01 trial (NCT#05259696) which is designed to assess the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of E-602. The first patient was dosed in March of this year.
Details of the poster presentation are as follows:
Presentation Type: Poster Presentation (Abstract: #772)
Title: A Phase 1/2 dose escalation/expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of E-602, a bi-sialidase fusion protein, in advanced cancer (GLIMMER-01)
Session: Poster Hall Session
Timing: November 11, 2022, 9:00 a.m. – 8:30 p.m. EST
Location: Hall C
The poster will appear on Palleon Pharmaceuticals’ website following the presentation.
About Palleon Pharmaceuticals
Palleon Pharmaceuticals, co-founded by Nobel laureate Carolyn Bertozzi, is a biotechnology company pioneering glyco-immunology drug development to transform the treatment of cancer and inflammatory diseases. The Company’s proprietary platforms overcome technical barriers unique to glycobiology to enable drug discovery, patient selection, and indication prioritization to de-risk clinical development. The company’s lead program in oncology, E-602, is a Phase 1/2, first-in-class, glyco-immune checkpoint inhibitor which restores anti-tumor immunity by enzymatically degrading immunosuppressive sialoglycans on hypersialylated tumors and immune cells. Palleon has a rich pipeline of additional drug candidates including several assets advancing toward IND-enabling studies.
Contacts
Media
Thomas Stephenson
Ten Bridge Communications
thomas@tenbridgecommunications.com
(857) 244-0246